Q2 2026 13F · SEC CIK 1913464

AlphaCentric Advisors LLC

Mutual fund managerFiled 2026-07-24 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $118.0M
Reported positions: 259
Top holdings a year, 3 yrs: -2.5%
Assets under management: $433.1M

AlphaCentric Advisors LLC is a mutual fund manager that reported 259 positions worth $118.0M in its Q2 2026 13F, filed 2026-07-24. Its largest holdings were Gilead Sciences Inc (GILD, 2.2%), Vertex Pharmaceuticals Inc (VRTX, 2.1%), Invitation Homes Inc (INVH, 1.9%). A portfolio copying its top holdings returned -2.5% a year over the last 3 years, against 22.0% for the S&P 500.

AlphaCentric Advisors LLC holdings largest 50 of 259 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

AlphaCentric Advisors LLC 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
GILDGilead Sciences Inc	2.2%	2.8%	20,426	+0.8%	$2.6M
VRTXVertex Pharmaceuticals Inc	2.1%	2.2%	5,002	+1.4%	$2.5M
INVHInvitation Homes Inc	1.9%	1.8%	73,000	+0.0%	$2.2M
AZNAstrazeneca PLC	1.8%	2.2%	11,394	+1.4%	$2.2M
ROIVRoivant Sciences Ltd	1.4%	1.3%	48,355	+1.4%	$1.7M
ARGNFArgenx SE	1.4%	1.3%	1,806	+0.7%	$1.7M
NBIXNeurocrine Biosciences Inc	1.4%	1.3%	9,727	+1.2%	$1.6M
INCYIncyte Corp	1.4%	1.3%	14,451	+1.4%	$1.6M
AXSMAxsome Therapeutics, Inc.	1.4%	1.1%	6,531	+1.4%	$1.6M
APGEApogee Therapeutics Inc	1.3%	1.0%	11,533	+1.4%	$1.5M
EEFTEuronet Worldwide Inc	1.2%	1.8%	20,000	-28.2%	$1.5M
AEVAAeva Technologies Inc	1.2%	0.7%	50,000	+0.0%	$1.4M
IWDIshares Tr	1.2%	2.5%	5,771	-51.2%	$1.4M
RPVInvesco Exchange Traded Fd T	1.2%	2.6%	12,122	-49.2%	$1.4M
QQQInvesco Qqq Tr	1.2%	—	1,860	—	$1.4M
QQQMInvesco Exch Traded Fd Tr II	1.2%	—	4,518	—	$1.4M
BFSSaul Ctrs Inc	1.1%	1.1%	35,000	+0.0%	$1.3M
INSMInsmed Inc	1.1%	1.4%	11,699	+31.8%	$1.2M
IONSIonis Pharmaceuticals Inc	1.0%	1.5%	15,430	-21.2%	$1.2M
ASNDAscendis Pharma A/s	1.0%	—	4,585	—	$1.2M
PTGXProtagonist Therapeutics Inc	1.0%	1.0%	9,171	+1.4%	$1.1M
BLDRBuilders Firstsource Inc	0.9%	0.8%	12,500	+25.0%	$1.1M
UMACUnusual Machs Inc	0.9%	—	50,000	—	$1.1M
HHHHoward Hughes Holdings Inc	0.9%	—	15,000	—	$1.1M
SHYIshares Tr	0.9%	0.8%	12,954	+36.9%	$1.1M
PSNLPersonalis Inc	0.9%	—	78,924	—	$1.1M
RYTMRhythm Pharmaceuticals Inc	0.9%	0.8%	9,449	+1.6%	$1.0M
STXSStereotaxis Inc	0.9%	1.1%	600,000	+0.0%	$1.0M
ROKRockwell Automation Inc	0.8%	0.7%	2,000	+0.0%	$990K
XMTRXometry, Inc.	0.8%	—	10,000	—	$965K
ABBVAbbvie Inc	0.8%	0.8%	3,613	+1.9%	$909K
JAZZJazz Pharmaceuticals PLC	0.7%	0.7%	3,613	+1.5%	$871K
TEMTempus Ai Inc	0.7%	—	15,000	—	$869K
PNNTPennantpark Invt Corp	0.7%	0.7%	250,000	+60.3%	$868K
AMGNAmgen Inc	0.7%	0.8%	2,362	+1.4%	$855K
BIIBBiogen Inc	0.7%	0.7%	3,891	+1.5%	$841K
AHRTAh Rlty Tr Inc	0.7%	0.6%	115,000	+0.0%	$814K
SMASmartstop Self Storag REIT I	0.7%	0.9%	25,000	-16.7%	$813K
RDWRedwire Corporation	0.7%	—	65,000	—	$795K
GMEDGlobus Med Inc	0.7%	0.6%	10,000	+33.3%	$790K
CTOCto Realty Growth Inc Com	0.6%	0.9%	35,000	-30.6%	$753K
CPRXCatalyst Pharmaceuticals Inc	0.6%	—	23,622	—	$742K
ONDSOndas Inc	0.6%	—	90,000	—	$742K
AATAmerican Assets Tr Inc	0.6%	0.6%	30,000	-14.3%	$741K
HALOHalozyme Therapeutics Inc	0.6%	—	9,426	—	$738K
MGTXMeiragtx Hldgs PLC	0.6%	—	54,469	—	$736K
AXRAmrep Corp	0.6%	1.3%	29,060	-34.7%	$733K
KRYSKrystal Biotech Inc	0.6%	—	1,945	—	$723K
MICCMagnum Ice Cream	0.6%	—	40,000	—	$696K
MANHManhattan Associates Inc	0.6%	—	5,000	—	$696K

What AlphaCentric Advisors LLC bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: —
3 years: -2.5% /yr; S&P 500 +22.0%
5 years: —

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$118.0M	259
Q1 2026	$100.1M	252
Q4 2025	$100.3M	249
Q4 2024	$100.2M	209
Q3 2024	$134.5M	230
Q2 2024	$135.8M	217
Q1 2024	$165.8M	228
Q4 2023	$149.0M	216
Q3 2023	$176.2M	234
Q2 2023	$180.1M	231
Q1 2023	$144.9M	209
Q4 2022	$101.2M	165

Questions about AlphaCentric Advisors LLC's portfolio

What stocks does AlphaCentric Advisors LLC own?

AlphaCentric Advisors LLC's latest 13F, for Q2 2026 and filed Jul 24, 2026, lists 259 positions worth $118.0M. The largest are Gilead Sciences Inc (GILD) at 2.2%, Vertex Pharmaceuticals Inc (VRTX) at 2.1%, Invitation Homes Inc (INVH) at 1.9%, Astrazeneca PLC (AZN) at 1.8% and Roivant Sciences Ltd (ROIV) at 1.4%.

What did AlphaCentric Advisors LLC buy last quarter?

In Q2 2026, AlphaCentric Advisors LLC added Pennantpark Invt Corp (PNNT) (+60.3% shares), Ishares Tr (SHY) (+36.9% shares) and Globus Med Inc (GMED) (+33.3% shares), compared with its Q1 2026 filing.

What did AlphaCentric Advisors LLC sell last quarter?

In Q2 2026, AlphaCentric Advisors LLC cut from its top 50 Ascendis Pharma A/s, cut from its top 50 Amprius Technologies Inc (AMPX), cut from its top 50 Braemar Hotels & Resorts Inc, cut from its top 50 Ingram Micro Hldg Corp (INGM), cut from its top 50 Intuitive Surgical Inc (ISRG), Ishares Tr (IWD) (-51.2% shares), Invesco Exchange Traded Fd T (RPV) (-49.2% shares) and Amrep Corp (AXR) (-34.7% shares), compared with its Q1 2026 filing.

How has AlphaCentric Advisors LLC's portfolio performed?

A portfolio copying AlphaCentric Advisors LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned -2.5% a year over the last 3 years, against +22.0% for the S&P 500.

When is AlphaCentric Advisors LLC's next 13F filing due?

13F filings are due 45 days after each quarter ends. AlphaCentric Advisors LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does AlphaCentric Advisors LLC manage?

AlphaCentric Advisors LLC reported $433.1M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $118.0M.